MI risks of diabetes drug

Rosiglitazone (Avandia) could increase the risk of MI by 43 per cent in patients with type-2 diabetes, US scientists claim.

The findings come from a meta-analysis of 42 trials, involving almost 18,000 patients aged an average of 56 years.

It also showed that the risk of death from all cardiovascular causes was 63 per cent higher in patients given rosiglitazone, compared with those given drug regimens excluding rosiglitazone.

Until more precise estimates of the risks of this treatment on cardiovascular health were carried out, providers should give 'careful consideration to the risks and benefits of their overall treatment plans', according to the researchers from the Cleveland Clinic in Ohio.

A spokeswoman for the MHRA said product information for rosiglitazone always had warnings on this risk and was updated by the European Medicines Agency in 2006. She added the safety of Avandia was being kept under review.

What do you think? Comment below or email us at GPletters@haymarket.com

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Close-up of a man loading a shotgun

BMA updates GP firearms guidance as digital marker goes live on EMIS

The BMA has updated its guidance for GPs on firearms licensing following the release...

Map pins

Severely underdoctored areas spread across nearly every NHS region

Severely underdoctored areas exist in nearly every NHS region across England, figures...


NHS bosses apologise for lack of consultation on practice takeover amid patient protests

NHS leaders have apologised and admitted they should have consulted more after choosing...


NHS backs 2.1% salaried GP pay rise from April as contract talks continue

NHS England has suggested salaried GPs are likely to receive a 2.1% pay rise from...


GP crisis threatens to wipe out millions of pounds in PCN income

General practice risks missing out on millions of pounds in funding this year because...

BMA sign

GPs reject 'insulting' contract as BMA issues stark warning over 'death of general practice'

GP leaders have rejected 'insulting' proposed changes to the GP contract for 2023/23,...